Neurocrine Biosciences
NBIX
#1203
Rank
S$20.87 B
Marketcap
$206.22
Share price
-0.96%
Change (1 day)
10.07%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.67

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $2.66. In 2022 the company made an earnings per share (EPS) of $2.19 an increase over its 2021 EPS that were of $1.29.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.6722.3%
2022$2.1969.47%
2021$1.29-78.21%
2020$5.92990%
2019$0.5481.82%
2018$0.30-113.5%
2017-$2.210.62%
2016-$2.2057.28%
2015-$1.4025.61%
2014-$1.1118.84%
2013-$0.94-1085.71%
2012$0.09508-89.71%
2011$0.92-500%
2010-$0.23-86.92%
2009-$1.77-43.48%
2008-$3.12-57.8%
2007-$7.4092.58%
2006-$3.84371.67%
2005-$0.81-52.76%
2004-$1.7336.56%
2003-$1.26-70%
2002-$4.21118.31%
2001-$1.938.4%
2000-$1.7848.86%
1999-$1.20-20%
1998-$1.49-479.31%
1997$0.39

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$2.84 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.75-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.02-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.37 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.00 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.53-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.64-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.12-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA